Form 4: Immuneering Corp Director Thomas J. Schall Acquires 35,000 Stock Options
SEC Form 4
Director Thomas J. Schall reports acquisition of 35,000 stock options in Immuneering Corp.
Summary
- Thomas J. Schall, a director of Immuneering Corp, filed a Form 4 disclosing a transaction.
- On March 11, 2024, Schall acquired 35,000 stock options with an exercise price of $5.93.
- The options vest in equal monthly installments over three years, starting April 11, 2024, and will be fully vested by March 11, 2027.
- Following the transaction, Schall directly owns 35,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director may signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of transaction: Acquisition of 35,000 stock options. |
| 03/11/2024 | Stock Option grant date. |
| 04/11/2024 | Vesting start date for the stock options. |
| 03/11/2027 | Full vesting date for the stock options. |
| 03/11/2034 | Expiration date for the stock options. |
| 03/12/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.